Differentiated breast cancer organoid plate
Highly standardized human breast cancer organoids in multi-well plate
Validated clinical outcome predictability
Human-based 3D tumor-microenvironment matching real life IC50 from standard of care (e.g. tumor cells, cancer-associated fibroblasts, resident immune cells)
Reproducible and differentiated organoids.
Our robust protocol, expertise and technology maintains above 500k cells per well enabling responses beyond assay quantification limits
Biologics and small molecule compatible
Human-relevant, PDMS free model for mABs, ADCs and drug candidates










Why choose our Mature Breast Cancer Organoids?
Drug Screening
Ready-to-use 24-well plates deliver abundant human biomaterial for integrated omics + HCS, enabling confident ranking across different cancer subtype
- HCS phenotyping
- Transcriptomics
- Proteomics
- Phosphoproteomic
Translational Precision & Biomarker Validation
3D human breast cancer organoids provide a highly relevant platform to validate predictive biomarkers and stratify responders with reproducible, standardized readouts.
- Receptor status
- Genomic drivers
- Response markers
- Resistance mechanisms
Tumor Microenvironment & Immuno-Oncology
Configurable co-culture with stromal components to fit your study – essential to study TME and immune interactions
- Cancer-associated fibroblasts crosstalk
- Immune assays
- Myeloid reprogramming
- Biologics/ADCs
Applications
Usable in your pharmaceutical research for the following:
- Target validation
- Lead indentification
- Lead optimisation
- Preclinical Safety
- ADME
- PKPD
- Tox efficacy
- Clinical translation
Frequently Asked Questions
No, our OrganoidPlates come precultured and loaded with your organoids of interest. Upon reception our plate is ready for assay after a half-day release protocol. This allows you to quickly start testing and not delay your experiments.
Our OrganoidPlate production methods do not natively include extracellular matrix. However, you can test using your own extracellular matrix after the release protocol (collagen-based reccomended).
On our custom options, you can select up to 5 cell types including:
- Organ-specific/Parenchymal cells (e.g: Adipocyte)
- Immune cells (e.g: Macrophages, Dendritic, Monocytes)
- Endothelial cells (e.g: HUVEC, CAEC, AdEC)
- Stromal cells (e.g: Fibroblasts, CAF, Adipocytes)
- Mesenchymal stem cells (e.g: ADSC)
You may aditionally choose your cell type ratios to best fit your purpose.
Our OrganoidPlate is currently only available in a standard 24 multiwell plate format.
Our main competitive advantage is being able to ship at room temperature enabling significantly lowered costs and logistical complexity of transport.
Depending on the type of plate, storage is possible from 3 days (AdipoPlate) to 14 days (MSC-based plate) at room temperature before the release protocol.
We do not recommend freezing the plates to avoid significant and massive cell death.
We do not supply patient-derived cells ourselves. However, our protocol has also been validated with patient-derived cancer cells, ensuring robust and reproducible outcomes. If you wish to apply our workflow to your own patient-derived material, please contact our experts; we will guide you on how to integrate your cells into our platform.
They Trust Us



















Ready to Accelerate your reasearch?
Get in Touch
contact@cherrybiotech.com
Phone
(+33) 9 87 04 70 35
Why Researchers Choose Us
- Proven track record in organoid technology
- Expert scientific support team
- Fast and reliable delivery
Looking for a more hand off experience?
Cherry Biotech’s CRO service is a step by step process designed to provide customers with accurate and reliable invitro data for drug development. Our 3D CRO service offers a diverse portfolio of biology models to improve the likelihood of success in your clinical trials.